ADA Scientific Sessions 2025 Abstract

Use of High-Potency GLP-1 Receptor Agonists with OpenAPS Automated Insulin Dosing Algorithm Eliminates Need for Meal Announcements to Achieve Glycemic Goals

By Tugce Akcan, Ryan S. Kingman, Marci Morgan, Rayhan Lal

Study in peopleInterventions

The paper

Tugce Akcan, Ryan S. Kingman, Marci Morgan, Rayhan Lal

Stanford

ADA Scientific Sessions 2025 Abstract, 13 Jun 2025

Presented at ADA Scientific Sessions 2025, poster 944-P

doi.org/10.2337/db25-944-p

Diabetes, Obesity & Metabolism4 Oct 2026
GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
Diabetes & Vascular Disease Research4 Oct 2026
SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs
Lancet4 Oct 2026
Orforglipron matches insulin glargine on cardiovascular safety
Diabetes, Obesity & Metabolism8 Oct 2026
Diabetes drug class linked to slightly less frailty progression